Bergen, Norway 20 December 2021
Development and preparations for first-in-human pilot study is on track asLifecare successfully has manufactured nanogranular tunneling strain (NTR)sensors on the prototype Sencell electrodes at the new Lifecare NanoBioSensorslaboratory. The manufacturing of NTR sensors is a major technical achievementfor Lifecare.
Read more in the Lifecare December newsletter: https://mailchi.mp/04dca0cc9477/newsletter-december-2021
This is LifecareLifecare is a Bergen-based technology company developing a miniaturizedimplantable long-term sensor for correct and continuous monitoring of bloodsugar in people with diabetes. The Company's patented technology also has thepotential for use in various biomarkers. Lifecare AS is listed on EuronextGrowth (LIFE).
Further information Joacim Holter, CEO, Lifecare AS, email@example.com,+47 40 05 90 40
This stock exchange announcement was published by Kine Hereid, InvestorRelations at Lifecare AS, on 20.12.21 at 14:10 CET.